Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease

Cardiovascular Pathology

Volumn 11, Issue 6, 2002, Pages 332-338

  Wong, Brian W C ^a   Wong, Donald ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atherosclerosis; Chemokines; CX3CR1; Diabetes mellitus; Fractalkine; Transplant vascular disease

Indexed keywords

CHEMOKINE; CHEMOKINE CX3CL1; CHEMOKINE CX3CR1; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; CHEMOKINE (C X3 C MOTIF) LIGAND 1; CHEMOKINE (C-X3-C MOTIF) LIGAND 1; CHEMOKINE RECEPTOR; CX3C CHEMOKINE; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ADVENTITIA; AGED; ARTERY MEDIA; ARTICLE; BLOOD VESSEL WALL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; FEMALE; FOAM CELL; HUMAN; HUMAN TISSUE; INTIMA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RIGHT CORONARY ARTERY; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; CORONARY BLOOD VESSEL; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; METABOLISM; MIDDLE AGED; ORGAN TRANSPLANTATION; PATHOLOGY; POSTOPERATIVE COMPLICATION; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOKINES, CX3C; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECEPTORS, CHEMOKINE; SINGLE-BLIND METHOD; VASCULAR DISEASES;

EID: 0036852450     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(02)00111-4     Document Type: Article

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
3. Hansson G.K. Immune and inflammatory mechanisms in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 1:1991;86-89.
4. Malik I.S. Inflammation in cardiovascular disease. J R Coll Physicians Lond. 34:2000;205-207.
5. Nicoletti A., Caligiuri G., Hansson G.K. Immunomodulation of atherosclerosis: myth and reality. J Intern Med. 247:2000;397-405.
6. Deng M.C., Plenz G., Erren M., Wilhelm M.J., Moennig G., Rothenburger M., Baba H.A. Transplant vasculopathy: a model for coronary artery disease. Herz. 25:2000;95-99.
7. Weis M., von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med. 51:2000;81-100.
8. Lin H., Wilson J.E., Roberts C.R., Horley K.J., Winters G.L., Costanzo M.R., McManus B.M. Biglycan, decorin, and versican protein expression patterns in coronary arteriopathy of human cardiac allograft: distinctness as compared to native atherosclerosis. J Heart Lung Transplant. 15:1996;1233-1247.
9. Lin H., Ignatescu M., Wilson J.E., Roberts C.R., Horley K.J., Winters G.L., Costanzo M.R., McManus B.M. Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant. 15:1996;1223-1232.
10. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature. 385:1997;640-644.
11. Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.A., Vath J., Gosselin M., Ma J., Dussault B., Woolf E., Alperin G., Culpepper J., Gutierrez-Ramos J.C., Gearing D. Neurotactin, a membrane anchored chemokine upregulated in brain inflammation. Nature. 387:1997;611-617.
12. Harrison J.K., Jiang Y., Wees E.A., Salafranca M.N., Liang H.X., Feng L., Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukocyte Biol. 66:1999;937-944.
13. Imaizumi T., Matsumiya T., Fujimoto K., Okamoto K., Cui X., Ohtaki U., Hidemi, Yoshida, Satoh K. Interferon-gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med. 192:2000;127-139.
14. Garton F.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., Raines E.W. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 276:2001;37993-38001.
15. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:1997;521-530.
16. Chapman G.A., Moores K.E., Gohil J., Berkhout T.A., Patel L., Green P., Macphee C.H., Stewart B.R. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol. 392:2000;189-195.
17. Yoneda O., Imai T., Goda S., Inoue H., Yamauchi A., Okazaki T., Imai H., Yoshie O., Bloom E.T., Domae N., Umehara H. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. 164:2000;4055-4062.
18. Fraticelli P., Sironi M., Bianchi G., D'Ambrosio D., Albanesi C., Stoppaciaro A., Chieppa M., Allavena P., Ruco L., Girolomoni G., Sinigaglia F., Vecchi A., Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 107:2001;1173-1181.
19. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiological flow. J Exp Med. 188:1998;1413-1419.
20. Goda S., Imai T., Yoshie O., Yoneda O., Inoue H., Nagano Y., Okazaki T., Imai H., Bloom E.T., Domae N., Umehara H. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol. 164:2000;4313-4320.
21. Foussat A., Coulomb-L'Hermine A., Gosling J., Krzysiek R., Durand-Gasselin I., Schall T., Balian A., Richard Y., Galanaud P., Emilie D. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol. 30:2000;87-97.
22. Robinson L.A., Nataraj C., Thomas D.W., Howell D.N., Griffiths R., Bautch V., Patel D.D., Feng L., Coffman T.M. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol. 165:2000;6067-6072.
23. Haskell C.A., Hancock W.W., Salant D.J., Gao W., Csizmadia V., Peters W., Faia K., Fituri O., Rottmann J.B., Charo I.F. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 108:2001;679-688.
24. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., Senaratne J., Green F.R., Tyson K., Boyle J., Shanahan C., Weissberg P.L., Gordon S., Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler, Thromb, Vasc Biol. 21(6):2001;923-929.
25. Kannel W.B., McGee D.L. Diabetics and cardiovascular disease: the Framingham study. JAMA, J Am Med Assoc. 241:1979;2035-2038.
26. Shantaram V. Pathogenesis of atherosclerosis in diabetes and hypertension. Clin Exp Hypertens. 21:1999;69-77.
27. Millonig G., Malcom G.T., Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis. 160:2002;441-448.
28. McDermott D.H., Halcox J.P.J., Schenke W.H., Waclawiw M.A., Merrel M.N., Epstein N., Quyyumi A.A., Murphy P.M. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 89:2001;401-407.
29. Moatti D., Faure S., Fumeron F., Amara Mel-W, Seknadji P., McDermott D.H., Debre P., Aumont M.C., Murphy P.M., de Prost D. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 97:2001;1925-1928.